26 Ozempic Statistics 2027: Market Growth, Usage Trends, and What They Mean for Women Seeking GLP-1 Treatment

Current data on GLP-1 medication adoption, affordability challenges, safety considerations, and demographic patterns shaping weight management options for women.

Short answer

US spending on GLP-1 medications rose more than 500% between 2018 and 2023, and 12% of US adults reported currently taking a GLP-1 drug in a November 2025 KFF poll. More than half of users (56%) said the medications were difficult to afford, and women reported higher use than men.

Majesta HealthReviewed by Ksenia Petrushkina, PA-C
Published Reviewed 15 min read

Current data on GLP-1 medication adoption, affordability challenges, safety considerations, and demographic patterns shaping weight management options for women.

The GLP-1 medication market has experienced explosive growth, with total US spending increasing over 500% from $13.7 billion in 2018 to $71.7 billion in 2023. Yet behind these impressive numbers lies a persistent challenge: affordability and access remain significant barriers for many patients, particularly women in their 40s to 60s who represent a major demographic using these medications. For women seeking physician-guided weight management through telehealth, platforms like Majesta Health provide information about compounded GLP-1 treatment options, transparent pricing, and ongoing care.

Key Takeaways

  • Market expansion continues: US spending on GLP-1 medications increased over 500% between 2018 and 2023, according to research published in 2025.
  • Adoption has increased: The percentage of US adults currently taking GLP-1 drugs reached 12% in a November 2025 survey, up from 6% approximately 18 months earlier.
  • Affordability remains critical: 56% of GLP-1 users reported difficulty affording their medications.
  • Women lead adoption: Women reported higher current GLP-1 use than men, with the highest usage among adults aged 50–64.
  • Discontinuation is common: A large US observational study found that one-year discontinuation rates varied substantially by diabetes status.

Understanding Ozempic and Semaglutide for Weight Loss

Ozempic is the brand name for semaglutide, an FDA-approved GLP-1 receptor agonist originally developed for type 2 diabetes management. While Ozempic is not FDA-approved specifically for weight loss, its active ingredient semaglutide is also used in Wegovy, which has received FDA approval for chronic weight management.

How semaglutide works for weight management

Semaglutide works by mimicking the GLP-1 hormone, which regulates appetite and blood sugar levels. This mechanism helps reduce hunger and increase feelings of fullness after eating.

1. An estimated 40.1 million Americans have diabetes

An estimated 40.1 million Americans had diagnosed or undiagnosed diabetes in 2023, according to the CDC's National Diabetes Statistics Report updated in 2026.

That represents approximately 12% of the US population. The estimate includes both type 1 and type 2 diabetes, rather than type 2 diabetes alone.

Type 2 diabetes accounts for the large majority of diabetes cases. Ozempic is FDA-approved for specific indications involving adults with type 2 diabetes and certain related health risks.

2. Around 40.3% of US adults have obesity

The prevalence of obesity among American adults reached 40.3% during August 2021 through August 2023, according to a CDC report published in February 2026.

The estimate covers adults aged 20 and older and uses measured height and weight collected through the National Health and Nutrition Examination Survey.

Obesity prevalence provides important context for demand for medical weight management treatments. However, obesity prevalence alone does not establish whether an individual should receive GLP-1 medication.

3. Severe obesity affects approximately 9.7% of adults

The CDC reported that 9.7% of US adults aged 20 and older had severe obesity in the August 2021–August 2023 survey period, using age-adjusted estimates.

Severe obesity is included within the overall obesity prevalence, so these figures should not be added together when describing the population.

These findings help explain the broader public health context surrounding prescription weight management. Treatment decisions still require evaluation of medical history, eligibility, and potential contraindications.

Distinction between brand-name and compounded semaglutide

Compounded medications are not FDA-approved as final products and are not generic versions of, equivalent to, or interchangeable with any FDA-approved medication.

Compounded semaglutide may be prepared by appropriately licensed compounding pharmacies when applicable legal requirements are met. For women researching compounded semaglutide, understanding the regulatory distinctions and the physician's role is essential.

The Role of Tirzepatide in Medical Weight Loss

Tirzepatide represents a newer class of weight management medication that acts on both GIP and GLP-1 receptors. This dual-agonist approach has generated significant interest in the medical community.

For women interested in tirzepatide options, Majesta's pricing includes compounded Tirzepatide/Glycine/B12 Injection through its Performance Plan, with all-inclusive monthly pricing covering physician consultation, medication if prescribed, and shipping.

As of November 20, 2026, enrollment remained in early access, subject to physician approval.

Ozempic and GLP-1 Market Statistics for 2027

The GLP-1 medication market has expanded substantially in recent years. The figures below distinguish historical spending data from current treatment usage and future market conditions.

4. US GLP-1 spending increased over 500% from 2018 to 2023

Total US spending on GLP-1 drugs increased by more than 500% between 2018 and 2023, according to a study published in JAMA Network Open in 2025.

The researchers analyzed outpatient prescription spending reported in national pharmaceutical transaction data. Their measurements were adjusted to 2023 dollars.

The study measured spending by patients and insurers at the point of sale. Its estimates did not account for all manufacturer rebates, discounts, or price concessions.

5. Annual GLP-1 spending reached $71.7 billion in 2023

US spending on GLP-1 receptor agonists reached $71.7 billion in 2023, compared with $13.7 billion in 2018.

Researchers reported average annual spending growth of 34% between 2018 and 2022, followed by a substantially larger increase between 2022 and 2023.

These values represent historical US outpatient prescription spending, not current global pharmaceutical revenue or a projection for 2027.

6. Ozempic spending reached $26.4 billion in 2023

US spending on Ozempic increased from $0.4 billion in 2018 to $26.4 billion in 2023.

This increase occurred as semaglutide-based treatments became a larger component of overall GLP-1 prescription spending.

The research measured US spending at the point of sale rather than the manufacturer's worldwide net sales. These measures should not be presented interchangeably.

7. Semaglutide and tirzepatide represented 70% of GLP-1 spending

By 2023, semaglutide products and Mounjaro together accounted for 70% of US spending on GLP-1 receptor agonists in the study.

The semaglutide category included Ozempic, Rybelsus, and Wegovy, while Mounjaro contained tirzepatide.

The percentage describes the products' share of spending, not the proportion of patients receiving these medications or their relative effectiveness.

US GLP-1 spending measure20182023
Total GLP-1 spending$13.7B$71.7B
Ozempic spending$0.4B$26.4B
Semaglutide and tirzepatide shareNot reported70%

Source: JAMA Network Open, 2025. Figures reflect US outpatient prescription spending, with monetary values expressed in 2023 dollars.

Usage and Adoption Trends

Understanding who uses GLP-1 medications and how adoption patterns have changed provides important context for treatment decisions.

8. About 12% of US adults currently take a GLP-1 drug

Approximately 12% of US adults reported currently taking a GLP-1 medication in KFF's October–November 2025 Health Tracking Poll.

The nationally representative survey included 1,350 US adults and covered medications used for weight loss, diabetes, and other health conditions.

The figure represents self-reported current use rather than independently verified prescription dispensing or treatment adherence.

9. Nearly 1 in 5 adults have tried a GLP-1 drug

About 18% of US adults reported having used a GLP-1 medication at some point in the November 2025 KFF survey.

This percentage includes both current and former users. It therefore differs from the smaller proportion reporting current treatment.

The survey included individuals using these medications for multiple medical indications, not exclusively for weight management.

10. Around 45% of adults reporting diabetes currently use GLP-1 drugs

Among US adults who reported having been diagnosed with diabetes, approximately 45% said they were currently taking a GLP-1 medication in 2025.

This figure comes from a self-reported survey rather than a national prescription database.

The survey's diabetes category was not limited to laboratory-confirmed type 2 diabetes. It should not be interpreted as a prescribing rate for every person with type 2 diabetes.

11. About 76% obtained GLP-1 medications through their doctor

Among adults who had ever used a GLP-1 medication, 76% reported obtaining it from their primary healthcare provider or another physician.

This finding comes from KFF's 2025 survey of adults with current or previous GLP-1 experience.

The reported source of medication describes where patients obtained treatment. It does not independently establish the quality of care, prescribing appropriateness, or follow-up received.

12. About 17% obtained GLP-1 medications from online providers

The same survey found that 17% of adults who had ever used GLP-1 medications obtained them from an online provider or website.

This reflects patients' reported acquisition channels rather than the total share of GLP-1 prescriptions written through telehealth.

Online treatment still requires appropriate medical evaluation and prescribing by a licensed clinician. The method of accessing care does not change the medication's regulatory status.

Side Effects and Safety Considerations

Understanding potential side effects helps patients make informed decisions about GLP-1 treatment and work effectively with their physicians to manage any issues that arise.

13. Gastrointestinal reactions affected 32.7% to 36.4% of Ozempic-treated patients

In pooled placebo-controlled Ozempic trials, gastrointestinal adverse reactions occurred in 32.7% to 36.4% of participants across the studied treatment groups.

By comparison, gastrointestinal adverse reactions were reported in 15.3% of participants receiving placebo.

These are clinical trial findings for FDA-approved Ozempic in people with type 2 diabetes. They are not established adverse-event rates for compounded semaglutide.

14. Nausea affected 15.8% to 20.3% of Ozempic-treated patients

Nausea was the most frequently reported individual adverse reaction in pooled placebo-controlled trials, affecting 15.8% to 20.3% of participants receiving Ozempic.

The corresponding rate among placebo recipients was 6.1%.

These results apply to the specific Ozempic treatment groups evaluated in the prescribing information and should not be generalized to every GLP-1 medication.

15. Diarrhea affected 8.5% to 8.8% of Ozempic-treated patients

Diarrhea occurred in 8.5% to 8.8% of Ozempic-treated participants in the pooled placebo-controlled trials.

The corresponding placebo group reported diarrhea at a rate of 1.9%.

Diarrhea is among the gastrointestinal effects described in the official prescribing information. Persistent symptoms should be discussed with the prescribing clinician, particularly when dehydration is a concern.

16. Vomiting affected 5% to 9.2% of Ozempic-treated patients

In the same pooled clinical trials, vomiting was reported by 5% to 9.2% of Ozempic-treated participants.

The placebo group reported vomiting at a rate of 2.3%.

The prescribing information also describes dehydration-related kidney injury as an important precaution. Persistent vomiting warrants prompt medical assessment.

17. Constipation affected 3.1% to 5% of Ozempic-treated patients

Constipation was reported in 3.1% to 5% of participants receiving Ozempic in pooled placebo-controlled trials.

The corresponding rate in the placebo group was 1.5%.

Constipation and other digestive symptoms may affect treatment tolerability. These clinical trial percentages should not be applied directly to compounded GLP-1 formulations.

Adverse reactionOzempic trial groupsPlacebo
Nausea15.8%–20.3%6.1%
Diarrhea8.5%–8.8%1.9%
Vomiting5%–9.2%2.3%
Constipation3.1%–5%1.5%

Source: Ozempic prescribing information, pooled placebo-controlled clinical trials in type 2 diabetes.

This is why ongoing physician oversight matters. Majesta's planned injection plans include monthly physician check-ins and care-team messaging to help patients manage potential side effects if treatment is approved and initiated.

Discontinuation and Adherence Patterns

Treatment adherence represents one of the most significant challenges in GLP-1 therapy, with tolerability, affordability, and other clinical and personal factors influencing continuation.

18. Nearly 64.8% of patients without diabetes discontinued within one year

A 2025 US observational study found that 64.8% of patients without type 2 diabetes discontinued GLP-1 treatment within one year.

The study examined adults with overweight or obesity who initiated medications with both diabetes and weight-management indications.

The findings apply to the defined study population and discontinuation measures. They do not establish that every GLP-1 user faces the same probability of stopping treatment.

19. About 46.5% of patients with type 2 diabetes discontinued within one year

The same study reported a 46.5% one-year discontinuation rate among patients with type 2 diabetes.

Discontinuation was substantially lower in this group than among patients without type 2 diabetes.

The analysis used healthcare data from 125,474 adults with overweight or obesity. Differences in clinical characteristics and treatment indications are important when interpreting these findings.

20. Treatment reinitiation reached 36.3% among patients without diabetes

Among patients who discontinued treatment, 36.3% without type 2 diabetes restarted a GLP-1 medication within one year of stopping.

The researchers evaluated reinitiation using longitudinal patient data and time-to-event statistical methods.

The figure describes patients who had already discontinued treatment and should not be interpreted as the percentage of all GLP-1 users restarting medication.

21. Reinitiation reached 47.3% among patients with type 2 diabetes

In the same study, 47.3% of patients with type 2 diabetes who discontinued GLP-1 treatment restarted within one year.

The reinitiation percentage was higher than among patients without type 2 diabetes.

These findings reflect observed treatment patterns, not a recommendation to restart medication. Decisions about stopping or restarting treatment require individualized clinical guidance.

Pricing and Accessibility Challenges

Affordability remains a major barrier to GLP-1 treatment, affecting patients across insurance categories.

22. About 56% of users find GLP-1 drugs difficult to afford

More than half of GLP-1 users, approximately 56%, reported difficulty affording their medications in KFF's 2025 survey.

The survey included current and former users with different insurance arrangements and reasons for taking these medications.

Cost challenges therefore cannot be explained solely by whether a person has insurance. Coverage rules and individual out-of-pocket obligations also affect affordability.

23. About 27% of users had insurance but paid the full medication cost

KFF reported that 27% of GLP-1 users had insurance but paid the entire medication cost themselves.

This percentage applies to the surveyed GLP-1 user population, not exclusively to patients whose insurance covered the prescription.

These findings explain why patients may examine self-pay treatment options. Any comparison should distinguish FDA-approved medications from compounded preparations and account for physician care and other charges.

This affordability challenge has driven interest in compounded options. Platforms offering transparent GLP-1 pricing with all-inclusive monthly costs help patients understand their actual expenses before starting treatment.

Women's Health Focus: Demographics and Treatment Patterns

Women report higher GLP-1 medication use than men, with particular concentration among adults in midlife.

24. Women reported 15% GLP-1 use compared with 9% among men

Current GLP-1 usage stood at 15% among women versus 9% among men in KFF's November 2025 survey.

These figures represent self-reported current use across medical indications, including diabetes and weight management.

The results show a gender difference in reported adoption. They do not establish that women necessarily respond better to GLP-1 medications.

25. Adults aged 50–64 had the highest reported usage at 22%

GLP-1 use peaked at 22% among adults aged 50–64 in the 2025 survey.

Adults aged 65 and older reported current use of 9%, demonstrating differences across age groups.

These are age-group estimates covering women and men together. They should not be presented as a women-only finding.

PopulationCurrent GLP-1 useSurvey period
All US adults12%Oct.–Nov. 2025
Women15%Oct.–Nov. 2025
Men9%Oct.–Nov. 2025
Adults aged 50–6422%Oct.–Nov. 2025

Source: KFF Health Tracking Poll, October 27–November 2, 2025.

This demographic pattern underscores why some telehealth platforms have chosen to focus specifically on women's health. For women in perimenopause or menopause seeking physician-guided treatment, understanding how the process works can help clarify what to expect.

Compounded GLP-1 Safety and Regulatory Considerations

Compounded versions of semaglutide and tirzepatide require particular attention to prescribing, preparation, medication safety, and regulatory requirements.

26. FDA received hundreds of adverse-event reports involving compounded GLP-1 medications

As of May 31, 2026, the FDA had received 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide.

The FDA cautions that reports may be incomplete or underreported and do not necessarily establish that the medication caused the reported event.

These report counts cannot be used to calculate the incidence of adverse reactions. They also should not be directly compared with clinical trial adverse-event percentages for FDA-approved medications.

Compounded medications are not FDA-approved as final products and are not generic versions of, equivalent to, or interchangeable with any FDA-approved medication. For patients interested in this pathway, working with licensed physicians and appropriately licensed compounding pharmacies is important.

How Majesta Supports Women Exploring GLP-1 Treatment

The latest Ozempic and GLP-1 statistics highlight growing medication use, affordability challenges, and the importance of ongoing medical supervision. For women considering treatment, choosing a provider involves more than comparing medication prices. Physician oversight, transparent costs, and continued support also matter.

Majesta is a LegitScript-certified telehealth platform focused on women's weight management, including the concerns that may arise during perimenopause and menopause.

Its physician-guided approach includes:

  • Licensed physician evaluation: Independent US-licensed physicians review medical histories and determine whether treatment is appropriate.
  • Transparent pricing: The Essential plan costs $159 for the first month, then $289/month. Performance costs $269 initially, then $399/month.
  • Ongoing clinical support: Injection plans include monthly physician check-ins and care-team messaging.
  • All-inclusive care: Plan pricing covers physician consultation, prescribed medication when approved, and shipping without separate membership fees.

Majesta's compounded medications are not FDA-approved as final products or interchangeable with FDA-approved medications. Enrollment remains subject to availability and physician approval.

Ready to explore your options? Start your assessment to review the next steps and join early access without payment or a medication order.

Before You Consider GLP-1 Treatment

Discuss your medical history, current medications, pregnancy plans, and possible contraindications with a licensed healthcare professional before considering GLP-1 medication. If you are pregnant, planning pregnancy, or using hormonal contraception, ask about medication-specific precautions.

FDA-approved semaglutide and tirzepatide products carry important warnings and contraindications. The prescribing clinician should review these with you, including a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Do not independently start, stop, or change medication without guidance from your prescribing clinician.

When to Get Help Right Away

Seek urgent medical attention for severe or persistent abdominal pain, especially when accompanied by vomiting. These symptoms may indicate pancreatitis or another serious medical problem requiring evaluation.

Call 911 for chest pain, difficulty breathing, fainting, or signs of a severe allergic reaction, such as swelling of the face, lips, tongue, or throat. Seek urgent medical evaluation for sudden vision loss or significant new visual symptoms.

Contact your prescribing clinician promptly about persistent vomiting, dehydration, severe gastrointestinal symptoms, or other concerning treatment-related effects.

This article is for informational purposes only and does not constitute medical advice, diagnosis or treatment. It does not recommend starting, stopping or changing any medicine.

Sources checked November 20, 2026.

Frequently Asked Questions

What is the difference between Ozempic and compounded semaglutide?

Ozempic is a brand-name, FDA-approved medication manufactured by Novo Nordisk for type 2 diabetes management and certain related indications. Compounded semaglutide is prepared by appropriately licensed compounding pharmacies when legal requirements are met. Compounded medications are not FDA-approved as final products and are not generic versions of, equivalent to, or interchangeable with FDA-approved medications like Ozempic.

Why do so many people discontinue GLP-1 medications within a year?

Research indicates that discontinuation rates vary by diabetes status and study population. A 2025 observational study reported one-year discontinuation rates of 64.8% among patients without type 2 diabetes and 46.5% among those with type 2 diabetes. Gastrointestinal adverse events and other patient characteristics were associated with differences in treatment continuation.

Are GLP-1 medications more commonly used by women or men?

Women reported higher current GLP-1 use than men in KFF's November 2025 survey, with 15% of women versus 9% of men reporting current use. The highest overall usage occurred among adults aged 50–64, including both sexes.

How much do GLP-1 medications typically cost?

Prices vary by medication, insurance coverage, and prescribing service. Even among people with insurance, out-of-pocket costs can be substantial. Majesta's company-confirmed Essential plan is $159 for the first month, then $289/month; Performance is $269 for the first month, then $399/month, subject to physician approval and enrollment availability. These compounded medications are not equivalent to FDA-approved brand-name products.

What kind of physician oversight should I expect with telehealth GLP-1 treatment?

Quality telehealth platforms provide evaluation by a US-licensed physician before any prescription is written. Look for providers offering regular physician check-ins, care-team messaging, and clear pathways to address questions or side effects throughout treatment. Treatment decisions, including whether a prescription is appropriate, remain with the licensed physician.

Sources

  1. 1.Spending on GLP-1 RAs · JAMA Network Open · accessed
  2. 2.National Diabetes Statistics Report · Centers for Disease Control and Prevention · accessed
  3. 3.Adult obesity prevalence · CDC, National Center for Health Statistics · accessed
  4. 4.GLP-1 Health Tracking Poll · KFF · accessed
  5. 5.Ozempic prescribing information · DailyMed, U.S. National Library of Medicine · accessed
  6. 6.Discontinuation and reinitiation · JAMA Network Open · accessed
  7. 7.Unapproved GLP-1 drug concerns · U.S. Food and Drug Administration · accessed
  8. 8.GLP-1 safety labeling changes · U.S. Food and Drug Administration · accessed

Ready to Join Early Access?

Join the early access list and we will email you when enrollment opens.

Start Your Assessment